robert rosiello  mckinsey  company  zoominfocom valeant pharmaceuticals to appoint robert l rosiello as chief financial officer  marketwatch latest news dow    nasdaq    sp      am et packing the pounds back on pigs  am et updated fda says it plans to lower nicotine in cigarettes to nonaddictive levels  am et updated dollar turns lower for the week following gdp report  am et updated set yourself up to get the most out of retirement  am et updated tesla earnings will model  live up to the hype  am et bitcoin prices rise as ether extends recent weakness  am et updated treasury yields dip after secondquarter gdp data  am et updated new rule forces big car makers into big changes in how they count revenues  am et updated these are the times you’re actually allowed to put money back into your ira  am et updated weekend sip is this the world’s first distilled nonalcoholic spirit  am et updated us gdp speeds up to  in nd quarter  am et updated time for gop to face reality everybody is going to have health insurance  am et updated stock market edges lower on track for weekly losses  am et updated howard marks says bitcoin isn’t real—and we can all blame millennials for its rise  am et minor lift for final consumer sentiment reading in july as partisan divide remains  am et us dollar holds decline after consumer sentiment data  am et treasury yields flat after consumer sentiment data  am et final umich consumer sentiment for july was   am et bojangles shares sink after revenue miss guidance cut  am et treasury to wind down the myra retirement savings program log in until london markets close currencies futures metals stocks home cnw group get email alerts valeant pharmaceuticals to appoint robert l rosiello as chief financial officer by published june    am et share laval quebec jun   canada newswire via comtex  valeant pharmaceuticals international inc vrx  vrx announced today that robert l rosiello was appointed as executive vice president and will take over the role of chief financial officer from howard schiller on july   mr schiller will remain on valeants board and is expected to serve as a consultant to valeant the board of directors and i are delighted that rob has agreed to join valeant said j michael pearson chairman and chief executive officer rob is someone i have worked closely with for  years i know his tremendous expertise in healthcare and in particular ma his unquestioned intellect and work ethic and integrity will prove to be of great value to the valeant organization and its shareholders i want to thank howard for his strong leadership to both myself and the entire organization these past few years and i will continue to rely on his valuable counsel as a member of our board of directors mr rosiello worked  years at mckinsey  company helping healthcare technology and consumer companies deliver growth through ma and business unit financial performance improvement as senior partner in charge of the global merger practice for the past decade mr rosiello led ma integrations for pharmaceutical specialty pharmaceutical and medical device companies in the us europe and asia mr rosiello serves on the board of catholic charities of new york the pew research center and the central selection committee of the morehead cain foundation he received his ba in economics from the university of north carolina where he was a morehead scholar he also earned an ms from the london school of economics and an mba from harvard about valeant valeant pharmaceuticals international inc nysetsxvrx is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology eye health neurology and branded generics more information about valeant can be found at wwwvaleantcom forwardlooking statements this press release may contain forwardlooking statements including but not limited to statements regarding the appointment of valeants chief financial officer forwardlooking statements may generally be identified by the use of the words anticipates expects intends plans should could would may will believes estimates potential target or continue and variations or similar expressions these statements are based upon the current expectations and beliefs of management of valeant and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements these risks and uncertainties include the risks and uncertainties discussed in valeants most recent annual or quarterly report and detailed from time to time in valeants other filings with the securities and exchange commission the sec and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forwardlooking statements these forwardlooking statements speak only as of the date hereof valeant undertakes no obligation to update any of these forwardlooking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes contact information laurie w little  laurielittlevaleantcom mediarenee e sotomeghan gavigan sard verbinnen  corsotosardverbcom  mgavigansardverbcom httpphotosprnewswirecomprnvarlalogo logo  httpphotosprnewswirecomprnhlalogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvaleantpharmaceuticalstoappointrobertlrosielloaschieffinancialofficerhtml source valeant pharmaceuticals international inc source valeant pharmaceuticals international inc copyright c  cnw group all rights reserved more from marketwatch more coverage howard marks says bitcoin isn’t real—and we can all blame millennials for its rise tesla earnings will model  live up to the hype hillary clinton’s new book ‘what happened’ makes for hilarious rrated internet quote references vrx   most popular the dark side of cruises cocacola to replace coke zero in us dow ends at record but tech slump weighs on sp  nasdaq if you can buy only one stock or etf make it this one how to fix wall street and bankers pay marketwatch partner center we want to hear from you join the conversation comment sponsored headlines advanced search stocks columns authors topics no results found valeant pharmaceuticals international inc us nyse vrx    volumem open high low pe ratio div yield market capb valeant pharmaceuticals to appoint robert l rosiello as chief financial officer – valeant skip to main content investor relations homestock information stock charthistorical price lookupinvestment calculatoradvanced fundamentals annual reports archivecorporate governance board of directorscommitteesgovernance documentssec filings analyst coveragenews releases events and presentationsinvestor information financial tear sheetshareholder servicesdocument requestsir and communications contactsemail alerts menu contact us locations home about valeant operational expertise investor relations career opportunities close investor relations homestock information stock charthistorical price lookupinvestment calculatoradvanced fundamentals annual reports archive corporate governance board of directorscommitteesgovernance documentssec filings analyst coveragenews releases events and presentationsinvestor information financial tear sheetshareholder servicesdocument requestsir and communications contactsemail alerts additional tools email page rss feeds home » investor relations » news releases »  » valeant pharmaceuticals to appoint robert l rosiello as chief financial officer share facebook googleplus twitter linkedin valeant pharmaceuticals to appoint robert l rosiello as chief financial officer june   laval quebec june   prnewswire  valeant pharmaceuticals international inc nyse vrx tsx vrx announced today that robert l rosiello was appointed as executive vice president and will take over the role of chief financial officer from howard schiller on july    mr schiller will remain on valeants board and is expected to serve as a consultant to valeant the board of directors and i are delighted that rob has agreed to join valeant said j michael pearson chairman and chief executive officer  rob is someone i have worked closely with for  years  i know his tremendous expertise in healthcare and in particular ma his unquestioned intellect and work ethic and integrity will prove to be of great value to the valeant organization and its shareholders i want to thank howard for his strong leadership to both myself and the entire organization these past few years and i will continue to rely on his valuable counsel as a member of our board of directors mr rosiello worked  years at mckinsey  company helping healthcare technology and consumer companies deliver growth through ma and business unit financial performance improvement  as senior partner in charge of the global merger practice for the past decade mr rosiello led ma integrations for pharmaceutical specialty pharmaceutical and medical device companies in the us europe and asia mr rosiello serves on the board of catholic charities of new york the pew research center and the central selection committee of the morehead cain foundation  he received his ba in economics from the university of north carolina where he was a morehead scholar  he also earned an ms from the london school of economics and an mba from harvard about valeant valeant pharmaceuticals international inc nysetsxvrx is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology eye health neurology and branded generics more information about valeant can be found at wwwvaleantcom forwardlooking statements this press release may contain forwardlooking statements including but not limited to statements regarding the appointment of valeants chief financial officer  forwardlooking statements may generally be identified by the use of the words anticipates expects intends plans should could would may will believes estimates potential target or continue and variations or similar expressions these statements are based upon the current expectations and beliefs of management of valeant and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements these risks and uncertainties include the risks and uncertainties discussed in valeants most recent annual or quarterly report and detailed from time to time in valeants other filings with the securities and exchange commission the sec and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forwardlooking statements these forwardlooking statements speak only as of the date hereof  valeant undertakes no obligation to update any of these forwardlooking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes contact information laurie w little  laurielittlevaleantcom   mediarenee e sotomeghan gavigan sard verbinnen  corsotosardverbcom  mgavigansardverbcom logo  httpphotosprnewswirecomprnhlalogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvaleantpharmaceuticalstoappointrobertlrosielloaschieffinancialofficerhtml source valeant pharmaceuticals international inc  back to news releases nysevrx tsx vrx copyright   valeant all rights reserved privacy policy terms  conditions site map marketwatchcom topics bulletin investor alert london markets close in currencies futures metals stocks topics istanbul brexit guns millennials immigration apple congatopicsmainhtml  subjects in the news us economy us politics earnings sales aerospace ice markets production iraq russia oil united kingdom europe european markets london markets health care income insurance people in the news jones edward trump donald woods tiger buffett warren putnam george clinton bill obama barack putin vladimir tillerson rex washington george ryan james walker david west david williams james gray john clooney george cruise tom jolie angelina companies in the news northrop grumman corp international data group new york mercantile exchange american international group health care insurance miners metal exchange target corp united national performance news corp jones oppenheimer international industries transport service capital one financial apple inc ebay inc organizations in the news american petroleum institute european union opec education department transportation department european central bank federal reserve bank of new york congress public service commission securities and exchange commission baseball nasdaq stock market consumers union world bank council on foreign relations security council senate boston college browse topics a b c d e f g h i j k l m n o p q r s t u v w x y z  log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest apacking the pounds back on pigs abreakingfda says it plans to lower nicotine in cigarettes to nonaddictive levels adollar turns lower for the week following gdp report aset yourself up to get the most out of retirement atesla earnings will model  live up to the hype abitcoin prices rise as ether extends recent weakness atreasury yields dip after secondquarter gdp data anew rule forces big car makers into big changes in how they count revenues athese are the times you’re actually allowed to put money back into your ira aweekend sip is this the world’s first distilled nonalcoholic spirit aus gdp speeds up to  in nd quarter atime for gop to face reality everybody is going to have health insurance astock market edges lower on track for weekly losses ahoward marks says bitcoin isn’t real—and we can all blame millennials for its rise aminor lift for final consumer sentiment reading in july as partisan divide remains aus dollar holds decline after consumer sentiment data atreasury yields flat after consumer sentiment data afinal umich consumer sentiment for july was  abojangles shares sink after revenue miss guidance cut atreasury to wind down the myra retirement savings program loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  robert l rosiello executive profile  biography  bloomberg july    am et healthcare equipment and supplies company overview of synergetics usa inc snapshotpeople  overviewboard memberscommittees executive profile robert l rosiello chief financial officer executive vice president and director synergetics usa incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr robert l rosiello also known as rob has been the chief financial officer and executive vice president at synergetics usa inc since october   mr rosiello served as an executive vice president of corporate development and strategy at valeant pharmaceuticals international inc from august  to december   he served as the chief financial officer and executive vice president of valeant pharmaceuticals international inc since july   and  june   respectively until august  mr rosiello worked  years at mckinsey  company helping healthcare technology and consumer companies deliver growth through ma and business unit financial performance improvement as senior partner in charge of the global merger practice for the past decade mr rosiello led ma integrations for pharmaceutical specialty pharmaceutical and medical device companies in the us europe and asia he has been a director of synergetics usa inc since october   mr rosiello serves on the board of catholic charities of new york the pew research center and the central selection committee of the morehead cain foundation he received his ba in economics from the university of north carolina where he was a morehead scholar he also earned an ms from the london school of economics and an mba from harvard universityread full background corporate headquarters  corporate centre driveofallon missouri united statesphone fax  board members memberships presentchief financial officer executive vice president and directorsynergetics usa inc education mba harvard universityms the london school of economics and political scienceba university of north carolina other affiliations harvard universityvaleant pharmaceuticals international incthe london school of economics and political scienceuniversity of north carolina annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact synergetics usa inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft valeant pharmaceuticals to appoint robert l rosiello as chief financial officer data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in data stocks events calendar sectors investment strategies etfs cefs mutual funds indices economic indicators economic calendar news tools dashboard fundamental chart technical chart equity screener fund screener comp tables timeseries analysis excel api support support topics contact us terms of use privacy policy about us careers financial glossary plans free trial sign in free trial sign in valeant pharmaceuticals to appoint robert l rosiello as chief financial officer june    laval quebec june   prnewswire  valeant pharmaceuticals international inc nyse vrx tsx vrx announced today that robert l rosiello was appointed as executive vice president and will take over the role of chief financial officer from howard schiller on july    mr schiller will remain on valeants board and is expected to serve as a consultant to valeantthe board of directors and i are delighted that rob has agreed to join valeant said j michael pearson chairman and chief executive officer  rob is someone i have worked closely with for  years  i know his tremendous expertise in healthcare and in particular ma his unquestioned intellect and work ethic and integrity will prove to be of great value to the valeant organization and its shareholders i want to thank howard for his strong leadership to both myself and the entire organization these past few years and i will continue to rely on his valuable counsel as a member of our board of directorsmr rosiello worked  years at mckinsey  company helping healthcare technology and consumer companies deliver growth through ma and business unit financial performance improvement  as senior partner in charge of the global merger practice for the past decade mr rosiello led ma integrations for pharmaceutical specialty pharmaceutical and medical device companies in the us europe and asiamr rosiello serves on the board of catholic charities of new york the pew research center and the central selection committee of the morehead cain foundation  he received his ba in economics from the university of north carolina where he was a morehead scholar  he also earned an ms from the london school of economics and an mba from harvardabout valeantvaleant pharmaceuticals international inc nysetsxvrx is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology eye health neurology and branded generics more information about valeant can be found at wwwvaleantcom forwardlooking statementsthis press release may contain forwardlooking statements including but not limited to statements regarding the appointment of valeants chief financial officer  forwardlooking statements may generally be identified by the use of the words anticipates expects intends plans should could would may will believes estimates potential target or continue and variations or similar expressions these statements are based upon the current expectations and beliefs of management of valeant and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements these risks and uncertainties include the risks and uncertainties discussed in valeants most recent annual or quarterly report and detailed from time to time in valeants other filings with the securities and exchange commission the sec and the canadian securities administrators which factors are incorporated herein by reference readers are cautioned not to place undue reliance on any of these forwardlooking statements these forwardlooking statements speak only as of the date hereof  valeant undertakes no obligation to update any of these forwardlooking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes contact information laurie w little laurielittlevaleantcom  mediarenee e sotomeghan gavigan sard verbinnen  corsotosardverbcom  mgavigansardverbcomlogo  httpphotosprnewswirecomprnhlalogo to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvaleantpharmaceuticalstoappointrobertlrosielloaschieffinancialofficerhtmlsource valeant pharmaceuticals international inc related stories new finance chief at valeant pharma sa breaking news   et valueact capital discloses sale of shares of valeant pharmaceuticals international inc pr newswire   et valeant pharmaceuticals to appoint robert l rosiello as chief financial officer pr newswire   et new indication for relistor cleared in europe sa breaking news   et relistorr receives european approval for expanded indication to treat all opioidinduced constipation globe newswire   et bayer may go after animal health businesses once it jettisons plastics unit sa breaking news   et critical alerts for organovo avago technologies valeant pharmaceuticals att and boeing released by investorsobserver pr newswire   et salix announces fda approval of xifaxan®  mg for the treatment of ibsd irritable bowel syndrome with diarrhea pr newswire   et fda clears two new treatments for ibsd sa breaking news   et pdufa date tomorrow for xifaxan expanded use sa breaking news   et advertisement  is a division of postmedia inc privacy faq create new password weve sent you an email with instructions to create a new password your existing password has not been changed close is a division of postmedia inc privacy faq